New drug combo shows promise in early cancer trial

NCT ID NCT05293496

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 22 times

Summary

This early-phase study tested a new combination of two drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants received the drugs every 4 weeks for up to 2 years. This is not a cure, but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Carolina BioOncology

    Huntersville, North Carolina, 28078, United States

  • Florida Cancer Specialists and Research Institute

    Sarasota, Florida, 34232, United States

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21287, United States

  • Stephenson Cancer Center, The University of Oklahoma

    Oklahoma City, Oklahoma, 73104, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, San Francisco

    San Francisco, California, 94115, United States

  • University of Pittsburgh Medical Center, Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia, 22908, United States

  • Weill Cornell Medicine

    New York, New York, 10065, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.